Phase 1b Study to Examine Neon Therapeutics’ Personal Neoantigen
Cancer Vaccine with KEYTRUDA® (pembrolizumab),
Merck’s Anti-PD-1 Therapy, and Chemotherapy
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Neon Therapeutics, a clinical-stage immuno-oncology company developing
neoantigen-based therapeutics, today announced that it has entered a
clinical trial collaboration with Merck (known as MSD outside the United
States and Canada) to evaluate Neon Therapeutics’ proprietary personal
neoantigen vaccine, NEO-PV-01, in combination with Merck’s anti-PD-1
therapy, KEYTRUDA® (pembrolizumab), along with chemotherapy.
NEO-PV-01 is Neon Therapeutics’ most advanced product candidate, and is
a personal neoantigen vaccine based on DNA mutations from each patients’
tumor. Neon Therapeutics and Merck will collaborate on a Phase 1b
clinical trial that will examine the safety, tolerability and
preliminary efficacy of NEO-PV-01 in combination with KEYTRUDA,
pemetrexed and carboplatin in patients with untreated advanced or
metastatic nonsquamous non-small cell lung cancer (NSCLC). Additionally,
the trial will assess neoantigen-specific immune responses in peripheral
blood and tumor tissue, and other markers of immune response.
“We believe there is a strong mechanistic rationale to explore the
combination of a personal neoantigen cancer vaccine, anti-PD-1 therapy
and chemotherapy,” said Richard Gaynor, M.D., president of research and
development at Neon Therapeutics. “Together with a growing set of
clinical collaborators, we are working to amass a diverse set of
clinical data to understand the potential of NEO-PV-01 to improve
durability and response rates in combination with multiple
The collaboration agreement is between Neon Therapeutics, Inc. and
Merck, through a subsidiary. Additional details were not disclosed.
About Neon Therapeutics, Inc.
Neon Therapeutics is a clinical-stage immuno-oncology company and a
leader in the field of neoantigen-targeted therapies, dedicated to
transforming the treatment of cancer by directing the immune system
towards neoantigens. We have pioneered a proprietary neoantigen platform
to develop neoantigen-targeted therapies using two distinct approaches.
In NEON / ONE, these neoantigens are specific to each individual. In
NEON / SELECT, these neoantigens are shared across subsets of patients
and tumor types. Our most advanced product candidate is NEO-PV-01, a
personal neoantigen vaccine, that is currently being evaluated in Phase
1 clinical trials. For more information, please visit www.neontherapeutics.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.
Ten Bridge Communications, Inc.
Dan Quinn, 781-475-7974